CN109758430A - 一种冬凌草甲素缓释片及其制备方法 - Google Patents
一种冬凌草甲素缓释片及其制备方法 Download PDFInfo
- Publication number
- CN109758430A CN109758430A CN201910234308.5A CN201910234308A CN109758430A CN 109758430 A CN109758430 A CN 109758430A CN 201910234308 A CN201910234308 A CN 201910234308A CN 109758430 A CN109758430 A CN 109758430A
- Authority
- CN
- China
- Prior art keywords
- oridonin
- sustained release
- release tablets
- preparation
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 title claims abstract description 119
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 title claims abstract description 119
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000001070 adhesive effect Effects 0.000 claims abstract description 25
- 239000000853 adhesive Substances 0.000 claims abstract description 24
- 235000019441 ethanol Nutrition 0.000 claims abstract description 24
- 150000001982 diacylglycerols Chemical class 0.000 claims abstract description 21
- 229920001661 Chitosan Polymers 0.000 claims abstract description 20
- 239000000314 lubricant Substances 0.000 claims abstract description 17
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 16
- 239000003765 sweetening agent Substances 0.000 claims abstract description 16
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 15
- 239000004973 liquid crystal related substance Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 13
- 238000000265 homogenisation Methods 0.000 claims description 12
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 8
- 229940083466 soybean lecithin Drugs 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 5
- 230000011218 segmentation Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000005507 spraying Methods 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 23
- 239000003814 drug Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000005336 cracking Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 241001646826 Isodon rubescens Species 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- -1 Ent-kaurane diterpenoid diterpene compound Chemical class 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- ONVABDHFQKWOSV-UHFFFAOYSA-N 16-Phyllocladene Natural products C1CC(C2)C(=C)CC32CCC2C(C)(C)CCCC2(C)C31 ONVABDHFQKWOSV-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- UYNPPIDGSVPVSW-UHFFFAOYSA-N ent-kaurane Natural products CC1(O)CC23CCC4C(CCCC4(C)C(=O)O)C2C=CC1C3 UYNPPIDGSVPVSW-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910234308.5A CN109758430B (zh) | 2019-03-26 | 2019-03-26 | 一种冬凌草甲素缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910234308.5A CN109758430B (zh) | 2019-03-26 | 2019-03-26 | 一种冬凌草甲素缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109758430A true CN109758430A (zh) | 2019-05-17 |
CN109758430B CN109758430B (zh) | 2020-10-13 |
Family
ID=66458753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910234308.5A Expired - Fee Related CN109758430B (zh) | 2019-03-26 | 2019-03-26 | 一种冬凌草甲素缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109758430B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727336A (zh) * | 2016-12-08 | 2017-05-31 | 广州中大南沙科技创新产业园有限公司 | 冬凌草甲素立方液晶纳米粒及其制备方法 |
-
2019
- 2019-03-26 CN CN201910234308.5A patent/CN109758430B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727336A (zh) * | 2016-12-08 | 2017-05-31 | 广州中大南沙科技创新产业园有限公司 | 冬凌草甲素立方液晶纳米粒及其制备方法 |
Non-Patent Citations (2)
Title |
---|
刘文: "《药用高分子材料学》", 31 July 2017, 中国中医药出版社 * |
魏跃胜: "《烹饪化学》", 31 August 2018, 华中科技大学出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN109758430B (zh) | 2020-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1048182C (zh) | 脂肪乳药物载体的制备方法 | |
JP5240822B2 (ja) | 多孔質セルロース凝集体及びその成型体組成物 | |
JP4969104B2 (ja) | 多孔質セルロース凝集体及びその成型体組成物 | |
JP5759457B2 (ja) | セルロースと無機化合物を含む複合粒子 | |
RU2734236C2 (ru) | Композиции бендамустина и циклополисахарида | |
EP3386480A1 (en) | Compositions of therapeutic substances, methods and uses thereof | |
CN105434337B (zh) | 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途 | |
CN107349175A (zh) | 一种负载脂肪褐变剂的微针贴片及其制备方法 | |
CN110087632A (zh) | 乳酸钙组合物和使用方法 | |
CN105853403A (zh) | 一种紫杉醇棕榈酸酯脂质体及其制备方法 | |
CN111317827A (zh) | 一种口服结肠靶向番茄红素纳米脂质体及其制备方法 | |
US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
CN1939298A (zh) | 硫酸舒欣啶固体和靶向制剂及其制备方法 | |
CN114712514B (zh) | 用于局部和全身性减脂的纳米制剂及其应用 | |
CN108926534A (zh) | Kgm改性卵磷脂载nmn透皮醇质体、制剂及其制备工艺与应用 | |
CN1726909A (zh) | 丁苯酞自乳化释药体系及其制备方法和应用 | |
CN109562068A (zh) | 含有弱酸性剂的微脂体组合物 | |
CN101062094B (zh) | 丹参总酚酸长循环脂质体及其制备方法 | |
CN109758430A (zh) | 一种冬凌草甲素缓释片及其制备方法 | |
CN1739525A (zh) | 一种新型的聚乙二醇衍生化磷脂包载前列腺素e1的纳米微粒给药系统 | |
CN102028655B (zh) | 扎那米韦固体脂质纳米粒的口服制剂及其制备方法 | |
CN108498455A (zh) | 一种油性水溶药物纳米晶及其制备方法 | |
CN102526111A (zh) | 一种含有蟾酥脂溶物的缓释微球及其制备方法与应用 | |
CN113786393A (zh) | 一种利伐沙班微球及其制备方法与应用 | |
CN103040750B (zh) | 阿戈美拉汀脂质体固体制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Jixiangshan beside yangtoukou flyover, No. 602, 817 Middle Road, Fuzhou City, 350000 Fujian Province Applicant after: Zhu Hongmei Address before: Huaiyin District of Ji'nan City, Shandong province 250117 Ji No. 440 Yan Lu Tumor Hospital of Shandong Province Applicant before: Zhu Hongmei |
|
CB03 | Change of inventor or designer information |
Inventor after: Chen Na Inventor after: Zhu Hongmei Inventor before: Zhu Hongmei |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200908 Address after: 250021, No. 324, No. seven, No. five, weft Road, Ji'nan, Shandong Applicant after: Shandong Provincial Hospital Affiliated to Shandong First Medical University Address before: Jixiangshan beside yangtoukou flyover, No. 602, 817 Middle Road, Fuzhou City, 350000 Fujian Province Applicant before: Zhu Hongmei |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201013 Termination date: 20210326 |